About REC-3565 REC-3565 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor designed using Recursion’s AI-driven multi-parameter optimization approach.

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement.

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

The Recursion OS — an integrated AI/experimental platform — was used to optimize for potency, selectivity, and PK/PD properties suitable for chronic dosing, enabling a candidate with potential ...